A

Amgen

Makes biotech medicines for serious illnesses

Patient Access Liaison - Krystexxa, Rare Disease

Full-TimeUpdated on 10/24/2026Deadline 11/9/26
$158.4k - $222.3k/yr
Senior, Expert
Bachelor's, Master's, PhD, Associate's
Ocala, FL, USA+2 moreMore locations: Gainesville, FL, USA | Jacksonville, FL, USA
In PersonField-based role; travel up to 50%, including occasional overnight and weekend commitments.
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • Doctorate degree, or a master's degree plus 2 years of patient services and/or access and reimbursement experience, or a bachelor's degree plus 4 years, or an associate's degree plus 8 years, or a high school diploma/GED plus 10 years of such experience for Level 5.
  • For Level 6, a doctorate degree plus 2 years of patient services and/or access and reimbursement experience, or a master's degree plus 4 years, or a bachelor's degree plus 6 years.
  • Ability to support buy-and-bill or infused pharmaceutical therapies.
  • Rare disease or orphan drug experience.
  • Clinical background such as nursing or allied health.
  • Understanding of reimbursement processes, including prior authorization, appeals, and denied claims management.
  • Knowledge of HIPAA guidelines and FDA regulatory requirements.
  • Familiarity with internal and Office of Inspector General compliance guidelines.
  • Ability to manage complex patient situations and resolve access barriers.
  • Experience working in cross-functional field teams.
  • Proficiency in Microsoft Office, customer relationship management (CRM) systems, artificial intelligence (AI), and relevant systems.
  • Knowledge of access and reimbursement, prior authorization processes, healthcare reimbursement systems, coding and billing, patient support programs, and compliance and privacy requirements.
  • Ability to respond rapidly to urgent access needs to prevent treatment delays or lapses.
  • Ability to operate effectively in matrix field environments.
  • Willingness to travel up to 50%, including occasional overnight and weekend commitments.
Responsibilities
  • Serve as a resource on patient access and reimbursement for infused and specialty therapies.
  • Assist patients, caregivers, and healthcare providers in navigating insurance benefits, prior authorization requirements, and reimbursement processes.
  • Support identification and resolution of access challenges, including coverage questions, prior authorization barriers, and denied claims.
  • Provide education regarding coding and billing considerations relevant to therapy access.
  • Develop relationships with patients and caregivers through phone, virtual, and in-person engagement.
  • Secure written or electronic patient HIPAA authorization within assigned geography.
  • Assess individual patient needs and provide education and resources that support access to therapy.
  • Educate patients on coverage considerations and the steps required to obtain prior authorization.
  • Provide information regarding co-pay assistance programs, national foundations, and free drug programs when appropriate.
  • Educate physician offices and sites of care on therapy coverage pathways and reimbursement processes.
  • Provide information regarding common prior authorization requirements, coding considerations, and billing practices.
  • Support healthcare providers and infusion centers in navigating reimbursement questions related to patient cases.
  • Investigate patient access challenges before and after infusion.
  • Support physician offices and sites of care in reviewing denied claims and identifying potential next steps.
  • Escalate complex or systemic reimbursement issues to appropriate internal stakeholders.
  • Partner with internal stakeholders, including Market Access, Medical Affairs, Advocacy, Case Managers, and Site of Care teams, to support patient access initiatives.
  • Coordinate with internal and external partners to ensure appropriate resources are available to support patient access.
  • Share field insights regarding payer policies and reimbursement challenges.
  • Adhere to company policies, compliance guidance, and applicable federal, state, and local regulations.
  • Ensure activities align with HIPAA privacy requirements and internal compliance guidelines.
  • Report adverse events and product complaints through established pharmacovigilance processes.
  • Maintain accurate documentation of activities and interactions in Amgen’s internal system.
Desired Qualifications
  • Strong analytical and problem-solving skills.
  • Ability to manage complex patient situations and resolve access barriers.
  • Experience working in cross-functional field teams.
  • Learning agility.
  • Decision quality.
  • Stakeholder engagement.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.